Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Other Non-Current Liabilities (2016 - 2025)

Guided Therapeutics (GTHP) has disclosed Other Non-Current Liabilities for 12 consecutive years, with $37000.0 as the latest value for Q4 2025.

  • Quarterly Other Non-Current Liabilities fell 68.64% to $37000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $37000.0 through Dec 2025, down 68.64% year-over-year, with the annual reading at $37000.0 for FY2025, 68.64% down from the prior year.
  • Other Non-Current Liabilities hit $37000.0 in Q4 2025 for Guided Therapeutics, down from $79000.0 in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $118000.0 in Q4 2024 to a low of -$38000.0 in Q3 2021.
  • Historically, Other Non-Current Liabilities has averaged $29416.7 across 4 years, with a median of $26000.0 in 2021.
  • Biggest five-year swings in Other Non-Current Liabilities: plummeted 115.62% in 2022 and later skyrocketed 361.54% in 2025.
  • Year by year, Other Non-Current Liabilities stood at $32000.0 in 2021, then tumbled by 115.62% to -$5000.0 in 2022, then soared by 2460.0% to $118000.0 in 2024, then crashed by 68.64% to $37000.0 in 2025.
  • Business Quant data shows Other Non-Current Liabilities for GTHP at $37000.0 in Q4 2025, $79000.0 in Q3 2025, and $60000.0 in Q2 2025.